NCT07746388

AUG 7, 2026 · PHASE 2 TRIAL

Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

ClinicalTrials.gov

This is a Phase 2, single-arm registry record with no reported results; it describes an adaptive design testing whether PD-L1–high resectable NSCLC patients can omit chemotherapy, but outcomes are not yet posted.